Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Metabolically Enhanced Lactic Acid Bacteria for Boosting Cancer Therapy

Project description

Boosting chemotherapy with smart bacteria

Cancer treatments often work unevenly. Some patients respond well, while others face harsh side effects with little benefit. One reason lies in differences in the gut microbiome, which can influence how the body reacts to therapy. The ERC-funded MELAB project aims to overcome this challenge by using metabolically enhanced lactic acid bacteria that deliver helpful metabolites directly to the gut, boosting chemotherapy effectiveness. Building on the ERC ModEM project, MELAB’s live biotherapeutics offer targeted metabolite delivery and optimal pharmacokinetics without genetic modification, allowing faster clinical translation. The project ultimately aims to create a safe, market-ready therapy that enhances treatment response and improves outcomes for cancer patients.

Objective

Inter-individual variation in cancer therapy responses is significant, with a substantial fraction of patients not responding to treatment. This exposes non-responders to harmful side effects without benefit and results in vast resources being spent on eventually ineffective treatments. A key factor behind this variability is differences in microbiome composition and metabolism. However, translating microbiome-cancer research into live bacterial therapies that modulate the microbiome is challenging due to its complexity and heterogeneity. This project addresses this challenge using safe, robust, metabolically enhanced lactic acid bacteria capable of delivering therapy-boosting metabolites in the gut. We focus on metabolites naturally produced by gut bacteria that have been shown to enhance the efficacy of chemotherapy. The engineered bacteria will function as live biotherapeutics, ensuring the targeted delivery of metabolites directly in the gut and thus achieving physiologically beneficial pharmacokinetics. Our approach is distinct from other microbiome therapies due to its clear mechanism of action and the use of a unique platform developed in the ERC project ModEM. It enables rapid metabolic enhancement without genetic engineering, thereby reducing regulatory hurdles and accelerating market entry. Overall, the MELAB project aims to translate core findings from the ModEM project into a novel therapeutic adjuvant with the potential to benefit cancer patients by increasing therapy response rates.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Net EU contribution
€ 150 000,00
Address
TRINITY LANE THE OLD SCHOOLS
CB2 1TN CAMBRIDGE
United Kingdom
Region
East of England East Anglia Cambridgeshire CC
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)